Cipla Ltd.

BSE: 500087 | NSE: CIPLA
Large Cap | Pharmaceuticals & Drugs
1440.30
2.95 (0.21%)
< Home < Back

Cipla partners with Sanofi India

Date: 27-03-2024

Cipla has entered into exclusive partnership with Sanofi India (SIL) and Sanofi Healthcare India (together referred as Sanofi India) for distribution and promotion of Sanofi India’s Central Nervous System (CNS) product range in India. As a part of this partnership, Cipla will be responsible for the distribution of Sanofi India’s six CNS brands including Frisium, a leading brand in the anti-epileptic medication category. 

While Sanofi India will continue to own, import, and manufacture its complete range of CNS products across plants in India and internationally, Cipla will leverage its capabilities and robust India-wide network of strong marketing and sales professionals, distributors, institutions, and market outreach programs to expand access to these treatments for patients who need them.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.